Moleculin Biotech (MBRX) Total Non-Current Liabilities (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Total Non-Current Liabilities of $7.1 million for Q4 2025, up 23.77% year-over-year from $5.7 million in Q4 2024, and up 19.12% quarter-over-quarter from $5.9 million in Q3 2025.
Moleculin Biotech (MBRX) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Moleculin Biotech's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $7.1 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 23.77% year-over-year to $7.1 million; the TTM figure through Dec 2025 stood at $7.1 million (up 23.77% YoY), while the FY2025 annual figure was $7.1 million, up 23.77% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $7.1 million, up from $5.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $8.2 million in Q2 2025, with the low at $3.4 million in Q2 2021.
- The 5-year median for Total Non-Current Liabilities is $5.9 million (2024), against an average of $5.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 81.39% in 2022, then slumped 34.83% in 2023.
- Moleculin Biotech's Total Non-Current Liabilities stood at $3.7 million in 2021, then soared by 39.86% to $5.2 million in 2022, then soared by 41.42% to $7.3 million in 2023, then fell by 21.57% to $5.7 million in 2024, then gained by 23.77% to $7.1 million in 2025.
- Business Quant data shows MBRX's Total Non-Current Liabilities at $7.1 million in Q4 2025, $5.9 million in Q3 2025, and $8.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Moleculin Biotech | 3.32 Mn | 3.32 Mn | - | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.46 Mn |
| Dec 31, 2025 | 7.08 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 8.21 Mn |
| Mar 31, 2025 | 7.22 Mn |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 5.98 Mn |
| Jun 30, 2024 | 6.17 Mn |
| Mar 31, 2024 | 5.86 Mn |
| Dec 31, 2023 | 7.29 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | 6.85 Mn |
| Mar 31, 2023 | 5.34 Mn |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 6.73 Mn |
| Jun 30, 2022 | 6.25 Mn |
| Mar 31, 2022 | 4.88 Mn |
| Dec 31, 2021 | 3.69 Mn |
| Sep 30, 2021 | 3.73 Mn |
| Jun 30, 2021 | 3.44 Mn |